|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
How Easily Can Johnson & Johnson (JNJ) Regain Lost Shelf Space?
7/31/2012 7:30:33 AM
Johnson & Johnson may be a venerable brand name among countless generations, but replacing its lost stature on store shelves may prove more difficult than some may assume. Between the sour economy, which has trained consumers to look for private-label bargains, and the ongoing lack of some J&J products, shoppers may take some convincing before they return to such stalwarts as Tylenol and Motrin, among other brand names. For instance, sales of private-label acetaminophen for adults rose nearly 14 percent last year from 2010, while J&J’s Tylenol was often out of stock. In the children’s pain category, sales of private-label acetaminophen rose more than 30 percent compared to 2010. Meawnhile, competing brands – Pfizer’s Advil, and Bayer’s Aleve and Bayer Aspirin – rose 7.3 percent, six percent and 8.9 percent, respectively, over 2010.
|
|
|
|
|
|
|
|
|
|
|